Abstract
Hand-foot syndrome (HFS) is one of the common adverse reactions in the treatment of malignant tumors, and its incidence is gradually increasing with the widespread use of antitumor drugs. HFS seriously affects patients' daily social and life, and even leads to drug dosage reduction or early discontinuation of medication, which delays treatment. Modern medicine has not yet fully clarified the understanding of its etiology and pathogenesis, the lack of uniform standards for the evaluation of therapeutic efficacy, and the poor effect of targeted systemic therapy. Chinese medicine classifies HFS into the category of "blood paralysis", and considers that the disease is located in the hands and feet, with deficiency as the main cause, and the deficiency as the underlying cause, and the mixture of deficiency and reality. BHD is from the book "Reform and Error Correction of Medical Forests" written by Qing Dynasty physician Wang Qingren, which has the effects of tonifying qi, activating blood and clearing collaterals. The formula is rigorous and well formulated, and is now widely used in all kinds of diseases with qi deficiency and blood stasis, with remarkable results. In recent years, with the rapid development of modern pharmacology, the research on the microscopic mechanism of action of BHD has been developing and deepening, which provides new ideas for the treatment of the disease. In this paper, we review BHD in HFS in the treatment of malignant tumors from the aspects of its formula and modern pharmacological research, with a view to providing clinical basis and reference for the future treatment of HFS of qi deficiency and blood stasis type by BHD.
Publisher
Century Science Publishing Co
Reference39 articles.
1. XI Chenxi, QIANG Wanmin, WANG Shurui, et al. Current status and research progress in the management of chemotherapy-induced hand-foot syndrome[J]. Nursing and Rehabilitation, 2023, 22(05):94-97.
2. Chen J, Wang Z. How to conduct integrated pharmaceutical care for patients with hand-foot syndrome associated with chemotherapeutic agents and targeted drugs[J]. Journal of Oncology Pharmacy Practice, 2021, 27(4): 919-929.
3. LIU Shujuan, WANG Wei. Progress in the study of immunoinflammatory mechanism of peripheral neuropathy caused by paclitaxel[J]. Shaanxi Medical Journal, 2022, 51(04):511-513.
4. Takahashi Y, Takei Y, Machida S, et al. Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine[J]. Journal of Obstetrics and Gynaecology Research, 2021, 47(2): 551-559.
5. Kuji M, Masuko H, Yamagami H, et al. Adjuvant chemotherapy with capecitabine for colon cancer-a case series[J]. Gan to Kagaku ryoho. Cancer & Chemotherapy, 2014, 41(12): 1752-1754.